Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial.
Lowell Anthony
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Marc Peeters
No relevant relationships to disclose
John Hainsworth
No relevant relationships to disclose
Eric Baudin
Consultant or Advisory Role - Novartis
Dieter Hoersch
Honoraria - Ipsen; Novartis; Pfizer
Research Funding - Covidien; Eckert and Ziegler ; Eckert and Ziegler ; Ipsen; ITG; Novartis; Pfizer
Judith Klimovsky
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Karen Grouss
Employment or Leadership Position - Novartis
Valentine Jehl
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Marianne Pavel
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer
Research Funding - Novartis
James Yao
Consultant or Advisory Role - Endo Pharmaceuticals; Ipsen; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Novartis